Defoslimod

DB20763InvestigationalSmall molecule

Defoslimod is a small molecule drug. The usage of the INN stem '-imod' in the name indicates that Defoslimod is a immunomodulator, both stimulant/suppressive and stimulant. Defoslimod is under investigation... Defoslimod is under investigation in clinical trial NCT01800812 (Effects of OM-174 in Adult Patients With Solid Tumors).

Formula / weight: C₅₃H₁₀₂N₂O₂₀P₂ · 1149.341 g/mol (avg)
Code names: OM-174

Resolves to

Compound

UNIIHC3530GGGGCAS171092-39-0

Structure

InChIKeyUUVVKHSZRKZOGM-CUECXTGJSA-NSMILES

CCCCCCCCCCC[C@@H](O)CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]2NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)O[C@H]1COP(O)(O)=O

Targets

O00206TLR4O60603TLR2

What you can answer from here — as of August 31, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Defoslimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account